Clinical Trial Update: A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the relative bioavailability of a VX-828 tablet formulation in cystic fibrosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• VX-828

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 1 | Status: COMPLETED